Exocell, Inc.
Philadelphia, PA, US· latest recorded location
Exocell, Inc. is named on 14 US grants and 2 published applications in this corpus. Its most frequent classification is A61K (Medicines and medical preparations).
- Granted patents
- 14
- Published applications
- 2
- Inventors
- 6
- Granted in 2026 so far
- 0
- Most recent grant
- 13 Jan 2004
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1991 | 3 | 0 |
| 1992 | 0 | 0 |
| 1993 | 2 | 0 |
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 2 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 3 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 1 |
| 2002 | 1 | 1 |
| 2003 | 1 | 0 |
| 2004 | 1 | 0 |
By publication year.
Technology areas
Share of 16 documents
- A61KMedicines and medical preparations8
- C07KPeptides6
- A61PTherapeutic uses of medicines3
- C07CAcyclic or carbocyclic compounds3
- G01NInvestigating or analysing materials by determining their chemical or physical properties3
- Y10TTechnical subjects covered by former us classification2
- Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests1
Recent patents
- Method for measurement of glycated hemoglobin by a rapid strip test procedure13 Jan 2004US 6,677,158 B2
- Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies22 Apr 2003US 6,552,077 B2
- Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies12 Mar 2002US 6,355,680 B1
- In vivo methods of treatment to prevent kidney dysfunction using substances that inhibit albumin glycation14 Dec 1999US 6,001,875 A
- In Vivo Methods to reduce hypercholesterolemia and improve vascular dysfunction30 Nov 1999US 5,994,401 A
Most cited
By later US patents
- Monoclonal antibodies against glycated albumin, hybrid cell lines producing these antibodies, and use therefore35US 5,223,392 A1993
- Monoclonal antibodies against glycated low density lipoprotein29US 5,494,791 A1996
- Treatment of complications of diabetes with substances reactive with the fructosyl-lysine structure in glycated albumin26US 5,518,720 A1996
- Genetically engineered immunoglobulins with specificity for glycated albumin17US 5,908,925 A1999
- Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies11US 6,552,077 B22003